Development Reports and Information Sample Clauses
The 'Development Reports and Information' clause requires one party, typically the developer, to provide regular updates and relevant information about the progress of a project to the other party. This may include periodic written reports, status updates, or access to documentation and records related to the development process. By mandating the sharing of timely and accurate information, this clause ensures transparency, enables effective monitoring of project milestones, and helps address issues proactively before they escalate.
Development Reports and Information. Gen-Probe and Chiron shall keep each other informed of their progress under the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. The parties shall develop reasonable procedures for requesting and delivering copies of such records to each other as may be necessary for the performance of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.
Development Reports and Information. Gen-Probe and Novartis each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments.
Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs. ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Development Reports and Information. ▇▇▇▇▇▇▇-▇▇▇▇▇ shall keep Ixsys informed as to the progress of the preclinical and clinical development and testing of all Products which ▇▇▇▇▇▇▇-▇▇▇▇▇ elects to develop and the preparing, filing and obtaining of the approvals necessary for marketing of all Products. Within thirty (30) days following each April 30, August 31 and December 31 following the commencement of preclinical development of a Product undertaken by ▇▇▇▇▇▇▇-▇▇▇▇▇, ▇▇▇▇▇▇▇-▇▇▇▇▇ shall provide to Ixsys a written report which shall summarize the progress of the development and testing of Products in preclinical development and clinical trials. In addition, ▇▇▇▇▇▇▇-▇▇▇▇▇ shall provide to Ixsys a minimum of six (6) months advance written notice of the contemplated filing of an Investigational New Drug application ("IND") with the FDA in the United States (or its equivalent in any other country), a written report which shall summarize all other regulatory submissions prior to the date of such submissions, and written notice of all approvals obtained promptly after obtaining such approvals.
Development Reports and Information. From and after the Effective Date, within [**] following the end of each [**] prior to Completion of the Arvinas Clinical Trials Transfer, Arvinas shall provide to the JSC (or, Novartis, if the JSC has been disbanded) (x) a reasonably detailed written report of the Arvinas Clinical Trial Activities conducted during such [**], as applicable, which report shall contain sufficient detail to enable the JSC (or Novartis, if the JSC has been disbanded) to assess Arvinas’ compliance with the Arvinas Development Plan [**] and this Agreement; and (y) access to or copies of any final written reports related to such Arvinas Clinical Trial Activities (or results of analyses thereof) as may be prepared by or on behalf of Arvinas or its Affiliates. Upon the reasonable request of Novartis from time to time, Arvinas shall make appropriate personnel with knowledge of the Arvinas Clinical Trial Activities available to Novartis to discuss such activities and provide or make available to Novartis all Data arising from the Arvinas Clinical Trial Activities in its possession or Control and not previously provided or made available.
Development Reports and Information. Following the expiration of the Research Program and during the Development Program, Bayer shall keep Immune Response informed as to the progress of the clinical development of each Product and the progress in preparing, filing and obtaining of the necessary marketing and pricing approvals to commercially sell and use the Product. Within thirty (30) days following the end of each June and December during the term of the Development Program, Bayer shall prepare, and provide to Immune Response, a summary written report which shall describe the progress of the clinical development and testing of Products in such clinical trials, the status of manufacturing such Product and the preparations to manufacture and supply such Product for any future clinical development and commercial sale, all regulatory filings and submissions made and all approvals obtained.
Development Reports and Information. From and after the Effective Date, within [***], Licensor shall provide to the DC (or, Novartis, if the DC has been disbanded): [***]. Upon the reasonable request of Novartis from time to time, Licensor shall make appropriate personnel with knowledge of the Licensor Clinical Trial Activities available to Novartis to discuss such activities; provided that Novartis shall reimburse Licensor for such assistance in accordance with Section 9.8 (Licensor Assistance), excluding DC meetings pursuant to Section 3.2 (Development Committee). 4.3 Regulatory Matters.
(a) Regulatory Submissions by Licensor.
(i) Notwithstanding any other provision of this Agreement, without Novartis’ prior written consent, neither Licensor nor its Affiliates shall submit or file any Regulatory Materials or otherwise communicate with any Regulatory Authority regarding Licensed Compounds or Licensed Products or the Exploitation thereof (including any Clinical Trial or other Development activities) other than regarding matters specifically related to the Licensor Clinical Trial Activities and in accordance with this Agreement.
(b) Regulatory Materials Received by Licensor. Licensor shall provide Novartis with: [***], in each case ((i) and (ii)), within [***] of their receipt or production of the foregoing, as applicable. If such [***], but not later than [***] after receipt of such correspondence.
Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.